BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart 2021;8:e001585. [PMID: 33653703 DOI: 10.1136/openhrt-2021-001585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jones S, Lopez-Candales A. Therapeutic advances in guideline-directed medical therapy for heart failure: the idealistic versus the pragmatic truth for vulnerable patients. Postgrad Med 2022. [PMID: 35929919 DOI: 10.1080/00325481.2022.2110797] [Reference Citation Analysis]
2 Straw S, Cole CA, McGinlay M, Drozd M, Slater TA, Lowry JE, Paton MF, Levelt E, Cubbon RM, Kearney MT, Witte KK, Gierula J. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clin Res Cardiol 2022. [PMID: 35781605 DOI: 10.1007/s00392-022-02053-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shanmugam N. The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics. Eur Cardiol 2022;17:e01. [DOI: 10.15420/ecr.2021.57] [Reference Citation Analysis]
4 Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. [PMID: 34859070 DOI: 10.3389/fcvm.2021.754499] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Chew DS, Mark DB. Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA Cardiol 2021;6:875-6. [PMID: 34037664 DOI: 10.1001/jamacardio.2021.1448] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Aimo A, Castiglione V, Vergaro G, Panichella G, Senni M, Lombardi CM, Emdin M. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev 2021. [PMID: 34291399 DOI: 10.1007/s10741-021-10146-1] [Reference Citation Analysis]